MolecularHealth has launched its TreatmentMap Targeted Panel, which covers 500 cancer-related genes, and the TreatmentMap Whole Exome test, which analyzes both somatic and germline mutations. Both tests also incorporate SafetyMap, a proprietary identification of drug target safety or resistance effects that uses the FDA’s Adverse Event Reporting System as an input for analysis. The tests are available for order in the US and Europe. MolecularHealth operates a CLIA-certified laboratory in The Woodlands, Texas.
Courtagen Life Sciences has launched two next-generation sequencing-based tests for neurodevelopmental disorders, developmental delay, intellectual disability, and autism spectrum disorder.
DevSeek screens around 100 genes known to cause neurodevelopmental disorders, including ASD, while DevAct screens for over 200 known treatable genetic disorders with the clinical presentation of ASD or other developmental disorders.